The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials
Published version of a preprint
Abstract
OBJECTIVE: To provide an updated synthesis on effects of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on weight, BMI, and waist circumference incorporating newer randomized controlled trials (RCTs), particularly in individuals with overweight or obesity. RESEARCH DESIGN AND METHODS: We systematically searched PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) for RCTs published from inception to 4 October 2024. The search was limited to RCTs evaluating the use of GLP-1 RAs for mean differences from baseline in weight, BMI, and waist circumference in adults with obesity or overweight with or without diabetes. Two independent reviewers performed the literature search and data extraction, resolving disagreements via consensus or third-reviewer consultation. RESULTS: Forty-seven RCTs were included, with a combined cohort of 23,244 patients. GLP-1 RAs demonstrated a mean weight reduction of −4.57 kg (95% CI −5.35 to −3.78), mean BMI reduction of −2.07 kg/m2 (95% CI −2.53 to −1.62), and mean waist circumference reduction of −4.55 cm (95% CI −5.72 to −3.38) compared with placebo. This effect was consistent across diabetes status, GLP-1 RA used, and route of administration. The greatest treatment benefit appeared to favor patients who were younger, female, without diabetes, with higher baseline weight and BMI but lower baseline HbA1c, and treated over a longer duration. Limitations include substantial statistical heterogeneity, in part due to broad inclusion criteria. However, this heterogeneity may improve generalizability by reflecting a wide range of study designs and patient populations. CONCLUSIONS: GLP-1 RAs demonstrated significant weight, BMI, and waist circumference reduction benefits in this meta-analysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent literature shows that GLP-1 receptor agonists are highly effective for weight loss and improving metabolic and cardiovascular health, often surpassing the results of lifestyle interventions alone, such as exercise and diet modification.”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [6]
In the citing paper
“GLP-1RAs, including liraglutide and semaglutide, can induce substantial weight loss (often 10–15% or more), improve cardiometabolic risk factors, including histological damage associated with metabolic dysfunction–associated steatohepatitis (MASH) (3), and reduce major adverse cardiovascular events in both diabetic and non-diabetic populations (1, 4–12).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [6]
In the citing paper
“GLP-1RAs, including liraglutide and semaglutide, can induce substantial weight loss (often 10–15% or more), improve cardiometabolic risk factors, including histological damage associated with metabolic dysfunction–associated steatohepatitis (MASH) (3), and reduce major adverse cardiovascular events in both diabetic and non-diabetic populations (1, 4–12).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [6]
In the citing paper
“GLP-1RAs consistently demonstrate significant weight loss (mean reductions of 7–9 kg of body weight over a period of about a year) and improvements in BMI, waist circumference, blood pressure, and lipid profiles in both diabetic and non-diabetic populations (5–7, 10, 23).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [6]
In the citing paper
“Current evidence strongly supports the efficacy of GLP-1 receptor agonists for inducing substantial weight loss, improving metabolic control, and reducing cardiovascular risk – often surpassing the short-term effects of exercise alone (4–10, 23).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Murray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30752-2 · Cited by 9,854
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2 · Cited by 5,177
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
Obesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology
Guyatt, G. H., Oxman, A. D., Schünemann, H. J., Tugwell, P., & Knottnerus, A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.011 · Cited by 3,094
Methley, A. M., Campbell, S., Chew-Graham, C., McNally, R., & Cheraghi-Sohi, S. (2014) · BMC Health Services Research · doi:10.1186/s12913-014-0579-0 · Cited by 2,706
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
Research works printed but not linked: 2
- World Health Organization, 2000, The Asia-Pacific Perspective: Redefining Obesity and Its Treatment.
- Higgins, 2023, Cochrane Handbook for Systematic Reviews of Interventions Version 6.4.
Cited by
Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists
Barrett, T. S., Hafermann, J. O., Richards, S., LeJeune, K., & Eid, G. M. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2025.3590 · Cited by 87
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 146
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension
Sioutas, G. S., Mualem, W., Reavey-Cantwell, J. F., & Rivet, D. J. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.2020 · Cited by 54
Genetic predictors of GLP1 receptor agonist weight loss and side effects
Su, Q. J., Ashenhurst, J. R., Xu, W., Tran, V., Wu, R. R., Weldon, C. H., Shi, J., Hicks, B., Bell, R. K., Bond, K. K., et al. (2026) · Nature · doi:10.1038/s41586-026-10330-z · Cited by 66
Kotecha, P., Huang, W., Yeh, Y.-Y., Narvaez, V. M., Adirika, D., Tang, H., Bernier, A. V., WESTEN, S. C., Smith, S. M., Bian, J., et al. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2025.3243 · Cited by 57
Chu, J., Zhang, H., Wu, Y. F., Huang, Y., Zhu, T., Zhou, Z., & Wang, H. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103464 · Cited by 44
Jackson, S. E., Brown, J., Llewellyn, C. H., Mytton, O. T., & Shahab, L. (2026) · BMC Medicine · doi:10.1186/s12916-025-04528-7 · Cited by 41
Alexander, G. C., Xiao, X., Dilek, S., Lewis, S. V., Deng, Q., Kim, M., Bolanle, D., Saldanha, I. J., & Mehta, H. B. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.8222 · Cited by 30
Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures
Liu, Y., Walzer, D., Schmitz, S. H., Shukla, A. P., Ma, X., Chirko, D., Pipia, I., Sathi, S., Shukairy, U., Greenberg, M. D., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag052 · Cited by 28
Forslund, M., Wändell, P. E., Forsberg, L., Österberg, M., Dagerhamn, J., Wernersson, E., Fredriksson, M. K., Ringborg, A., & Hirschberg, A. L. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag033 · Cited by 38
Messiah, S. E., Ernest, D. K., Atem, F., Qureshi, F. G., Mathew, M. S., Francis, J., Wheelington, A., Allicock, M. A., Cartwright, B. R., Schneider, B. E., et al. (2025) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2025.114564 · Cited by 17
GLP-1RA precision medicine in people with type 2 diabetes: current insights and future prospects
Cardoso, P., Dennis, J., & Pearson, E. R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194742 · Cited by 20
Özbek, L., Shah, E., Al-Shiab, R., İnal, A., Güldan, M., Afşar, B., Covic, A. C., & Kanbay, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70699 · Cited by 22
GLP-1 agonists and exercise: the future of lifestyle prioritization
Codella, R., Senesi, P., & Luzi, L. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1720794 · Cited by 16
Fitch, A., Gigliotti, L., & Bays, H. E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100205 · Cited by 14
Ateiwi, Y. A., Mahmood, R. R., Wong, H. J., Low, C. E., Yau, C. E., Lee, A. R. Y. B., Eng, P. C., Lee, M., Chan, M. Y., & Sia, C. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113158 · Cited by 17
Self-citationLorenc, Z. P., Somenek, M. T., Nguyen, T. Q., Garimella, S., Hicks, J. L., Le, J. H. T. D., & Meckfessel, M. (2025) · Aesthetic Surgery Journal · doi:10.1093/asj/sjaf240 · Cited by 15
Vozza, A., Triggiani, D., Fanelli, M., Lisco, G., Coletto, D., Custodero, C., Volpe, S., Racaniello, D., Colaianni, V., Lavarra, V., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1674308 · Cited by 12
Lifestyle management approaches for obesity
Landry, M. J., & Bagha, Z. M. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.08.022 · Cited by 15
Inbaraj, G., Bajaj, S., Misra, P., Kandimalla, N., Thapa, A., Ghosal, A., Sharma, U., charles, P., Pobbati, H., Hashmi, I., et al. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.103036 · Cited by 13
The Land That Time Forgot? Planetary Health and the Criminal Justice System
Logan, A. C., Berryessa, C. M., Callender, J. S., Caruso, G. D., Hagenbeek, F. A., Mishra, P., & Prescott, S. L. (2025) · Challenges · doi:10.3390/challe16020029 · Cited by 14
Addressing the risk of ocular complications of GLP ‐ 1RAs ; a multi‐disciplinary expert consensus
Carter, P., Simó, R., Lövestam‐Adrian, M., Pearce, I., Bain, S. C., Dinah, C., Davies, S. J., Strain, W. D., Burgess, P. I., Gamble, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70160 · Cited by 16
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 23
Dietary and pharmacological energy restriction and exercise for healthspan extension
Cagigas, M. L., Ciutiis, I. D., Masedunskas, A., & Fontana, L. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.04.001 · Cited by 13
Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review
Dias, D. D., Vasconcelos, A. R., Souza, A. C. R., Menezes, C. D., Silva, I. S. T. E., & Name, J. J. (2025) · Obesities · doi:10.3390/obesities5040088 · Cited by 8
Meng, L., Chuang, H.-M., Lai, H., Chen, H., Yang, K., Chen, L., & Hsiao, F. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103332 · Cited by 8
Pirera, E., Raimondo, D. D., D’Anna, L., & Tuttolomondo, A. (2025) · Pharmaceuticals · doi:10.3390/ph18091337 · Cited by 8
A horizon scan of biological conservation issues for 2026
Sutherland, W. J., Butchart, S. H. M., Clarke, S. J., Doar, N., Doran, H., Douglas, I. C., Field, D. J., Fleishman, E., Gaston, K. J., Herbert‐Read, J. E., et al. (2025) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2025.10.016 · Cited by 11
Adams, R. N., Athinarayanan, S. J., Zoller, A. R., McKenzie, A. L., & Ratner, R. E. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16525 · Cited by 7
Ganson, K. T., Testa, A. M., Lavender, J. M., & Nagata, J. M. (2025) · Eating Behaviors · doi:10.1016/j.eatbeh.2025.102013 · Cited by 8
Ho, L. T., Fang, Y., Hsu, P.-S., Wang, J., & Tsai, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-19657-5 · Cited by 12
Johnson, H. H., Clift, A. K., Reisel, D., & Huang, D. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70244 · Cited by 7
Wang, Q., Wu, D., & Huang, Y. T. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1682814 · Cited by 11
Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies
Rejili, M. S., Hussain, M. S., Khan, Y., Haouala, F., Ganesan, S., Sahoo, S., Pal, A., & Arora, V. (2025) · Vascular Pharmacology · doi:10.1016/j.vph.2025.107563 · Cited by 7
Heo, K. Y., Barchick, S. R., Sowa, A. M., Chao, M., Rajan, P. V., Goh, B. C. K., & Yoon, S. T. (2025) · The Spine Journal · doi:10.1016/j.spinee.2025.12.019 · Cited by 7
Al-Awadi, A. A., Alroudhan, D., Alsaeed, D., Almarshad, B. W., Alshehabi, D. H., Al‐Lahou, B., Mashankar, A., Al‐Ozairi, E., & Gray, S. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-116911 · Cited by 16
Weight regain after cessation of GLP-1 drugs
Sun, Q. (2026) · BMJ · doi:10.1136/bmj.r2586 · Cited by 6
The Conundrum of Exercise for Weight Management in the GLP-1 Receptor Agonist Era
Lieberman, D. E., Aslan, D. H., & Heymsfield, S. B. (2026) · JAMA · doi:10.1001/jama.2026.5537 · Cited by 8
Garg, S. K., Aktürk, H. K., Garg, S., Beck, R. W., Bellini, N. J., Bjornstad, P., Carlson, A. L., Carroll, J., Close, K., Block, C., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261449879 · Cited by 8
Natale, A., & Mohanty, S. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf460 · Cited by 5
Meißner, N., Ramos‐Pascual, S., Ortwig, K. A., van Rooij, F., Schrednitzki, D., Stöve, J., & Halder, A. M. (2026) · Journal of Experimental Orthopaedics · doi:10.1002/jeo2.70651 · Cited by 7
Genetic architecture of obesity and advances in precision pharmacotherapy: a comprehensive review
Kavaja, F., Liehr, T., & Temaj, G. (2026) · Acta Biochimica Polonica · doi:10.3389/abp.2026.15484 · Cited by 6
Mechanical ventilation for ICU patient with obesity: current best practices and future directions
Kitisin, N., Caroli, A., Ferreira, J. C., Hikasa, Y., Ke, L., Nübel, J., Raykateeraroj, N., Thille, A. W., Ueno, R., Hernández, G., et al. (2026) · Intensive Care Medicine · doi:10.1007/s00134-026-08397-3 · Cited by 9
Ho, M. J., Liew, C. F., Tan, N. A. M. R., Morita, A., & Oon, H. H. B. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2665732 · Cited by 7
Ilie, I. R. P., Ghibu, S., Butucă, A., Dobrea, C. M., Frum, A., Homorodean, C., Chiş, A. A., & Morgovan, C. (2026) · Pharmaceuticals · doi:10.3390/ph19060876 · Cited by 7
Hsiao, C.-C., Chen, M., Liu, C. Y., Chan, C.-Y., Fang, Y.-W., Liou, H., & Tsai, M. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf172 · Cited by 11
Ingestive Behavior and Precision Nutrition: Part of the Puzzle
Biruete, A., Buobu, P. S., Considine, R. V., Hoxha, E. M., Eicher‐Miller, H. A., Kinzig, K. P., Panjwani, A. A., Running, C. A., Rutigliani, G., Savaiano, D. A., et al. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100531 · Cited by 7
Jackson, S. E., Brown, J., Llewellyn, C. H., Mytton, O. T., & Shahab, L. (2025) · medRxiv · doi:10.1101/2025.06.06.25329114 · Cited by 5
Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review
Dang, V., Sambuco, N., Yammine, L., & Versace, F. (2026) · doi:10.64898/2026.01.31.702984 · Cited by 4
Gut Peptide Alterations in Type 2 Diabetes and Obesity: A Narrative Review
Tzeravini, E., Simati, S., Anastasiou, I. A., Dalamaga, Μ., & Kokkinos, A. D. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00687-7 · Cited by 8
Alhussain, K., AlShakhs, Z. H., Albaqshi, L., Alshaqaqiq, F., Alrabiah, M., & Tripathi, R. (2026) · Healthcare · doi:10.3390/healthcare14030345 · Cited by 4
Choudhury, I., Ward, J. H., Mahesh, S., Alam, U., Azmi, S., & Anson, M. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.02.010 · Cited by 5
Wang, Y., Liu, J., Verbeke, K., Gasaly, N., Akkerman, R., & de Vos, P. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100647 · Cited by 11
The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss
Henriksen, K., Chakravarthy, M. V., Bager, C. L., Larsen, A. T., Mohamed, K. E., & Karsdal, M. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16379 · Cited by 4
Barbosa, L. A. D. S., Almarie, B., & Moreira, E. L. G. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00875-y · Cited by 6
Effects of Glucagon-Like Peptide-1 Receptor Agonist on Facial Landmarks
Chen, T. H.-T., Li, J., Hellbusch, D., & Tao, J. (2025) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000003070 · Cited by 4
Liraglutide for adults living with obesity
Meza, N., Bracchiglione, J., Liquitay, C. M. E., Madrid, E., Varela, L. B., Guo, Y., Urrútia, G., er, S. F. S., Tiller, S., Shokraee, K., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016017 · Cited by 16
Body image in the age of GLP-1s: Emerging questions for research and practice
Craddock, N., & Schneider, J. (2026) · Body Image · doi:10.1016/j.bodyim.2026.102095 · Cited by 5
Liechti, M., Schurz, A. P., Marnef, A. Q., Taeymans, J., Clijsen, R., Baur, H., Lutz, N., Deliens, T., Clarys, P., Nijs, J., et al. (2025) · Physical Therapy · doi:10.1093/ptj/pzaf097 · Cited by 3
Florescu, A. G., Pucerea, S. A., Floria, M., Rusu, E., Cuiban, E., Jinga, M., Galrinho, R. D., & Stanciu, S. M. (2025) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2025.128.6.9 · Cited by 8
Scagliusi, F. B., Gualano, B., Andreassen, P., SturtzSreetharan, C., Jensen, S. D., & Brewis, A. (2025) · Obesity · doi:10.1002/oby.70069 · Cited by 5
Shirmard, F. O., Pourfaraji, S. M., Omouri‐Kharashtomi, M., & Amani, A. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04496-5 · Cited by 5
Intestinal-related substances in obesity regulation: A comprehensive review
Wang, S.-Y., Zhang, M.-Z., Chen, Z., Li, Z.-M., Xie, C., Yang, G., Xu, B., & Xu, T. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i4.111082 · Cited by 5
Huu, T. N., Thanh, H. D., Kim, M.-K., Sah, D. K., Trinh, V. H., Yoon, H. J., Choi, J. M., Lee, G.-H., Kim, S., & Lee, S.-R. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00094-x · Cited by 3
AbuAlhommos, A. K., Hawaj, M. A. A., Alrasheed, S. Y., Alessa, R. A., Alhussain, A. Y., Alabdulkareem, R. A., & Alzamil, R. I. A. (2026) · Medicine · doi:10.1097/md.0000000000046957 · Cited by 5
Villelabeitia, I. K., COHEN, R. V., & le Roux, C. W. (2026) · Heart · doi:10.1136/heartjnl-2025-326812 · Cited by 4
Hindi, A. M. K., Mekkawy, M. A., & Shokr, H. (2026) · Pharmaceuticals · doi:10.3390/ph19030365 · Cited by 6
Evolving Role of GLP-1 Therapies in Liver Disease
Lindsay, M., Arndt, G., Wieland, A. C., & Jensen, T. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00988-2 · Cited by 3
Logan, A. C., Caruso, G. D., & Prescott, S. L. (2025) · Societies · doi:10.3390/soc15110305 · Cited by 7
Elbatreek, M. H., Li, Z., Yu, X., Gehred, N., Gromova, T., Chen, J., Muraoka, N., Jensen, M. B., Kartha, V. K., Carrico, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.26.678829 · Cited by 3
Lee, Y. A., Huang, Y., Dai, H., Yuce, T. K., Shah, V. N., Bian, J., & Guo, J. S. (2025) · medRxiv · doi:10.1101/2025.11.10.25339913 · Cited by 3
Griffiths, A., Shannon, O. M., Spreckley, M., Austin, K., Fallows, E., Clare, K., Ells, L. J., & Matu, J. (2025) · medRxiv · doi:10.64898/2025.12.11.25342052 · Cited by 4
Elbashir, R. M. A., Elbashir, A., Basake, R. U., Mohieldin, A. Z. A., Elhaj, N. A. E., Ebrahim, F. E. M., Ahmed, W. G., & Mahgoub, O. A. M. (2025) · Cureus · doi:10.7759/cureus.95938 · Cited by 3
Boukind, A., He, K., Speller, N., & Badran, S. M. (2025) · Aesthetic Surgery Journal · doi:10.1093/asj/sjaf244 · Cited by 7
Kamrul-Hasan, A. B. M., Chatterjee, S., Nagendra, L., Dutta, D., & Pappachan, J. M. (2025) · Postgraduate Medical Journal · doi:10.1093/postmj/qgaf238 · Cited by 5
Schmidt, P. H. S., de Souza, V. S. N., Machado, L. G., Rodrigues, J. V. A., da Cruz, J. V. R., de Souza, L. S. N., dos Santos, B. E., Hohl, A., Ronsoni, M. F., & van de Sande‐Lee, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70529 · Cited by 7
Berggren, J., Lindqvist, A., Isaksson, A., Hedenbro, J., & Lindqvist, A. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.02.011 · Cited by 2
Prasad, A., Arora, A., Arora, A., Vaid, J., & Khan, A. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70515 · Cited by 3
Gunasekaran, P., Inban, P., Agrawal, A., Thai, A., Aravazhi, P. S., Tariq, H., Prajjwal, P., & John, J. (2026) · Disease-a-Month · doi:10.1016/j.disamonth.2026.102113 · Cited by 3
Buonanno, S., Gaggiano, C., Baldi, C., Cantarini, L., Frediani, B., & Gentileschi, S. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16060284 · Cited by 3
Khan, M. Q., Becchetti, C., Jouid, M. R., Mortuza, R., Panda, S., Pierluissi, V., Stegagnini, M., Punchhi, G., Bajunayd, A., Viganò, R., et al. (2026) · Liver Transplantation · doi:10.1097/lvt.0000000000000917 · Cited by 2
Stamouli, E., Trakatelli, C., Sarigianni, M., Kitsios, K., & Kotsis, V. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03239-4 · Cited by 3
Chemobiology of Obesity and Advances in Bariatrics: A Systematic Review
Onyebuchi, C., Rachael, A. A., Aizebhughele, K., Eze, C., Jeremiah, C. S., Uzochukwu, O. H., Onyebuchi, D. I., & Onyebuchi, A. O. (2025) · medtigo Journal of Medicine · doi:10.63096/medtigo30623130 · Cited by 2
Baidya, J., Dalton, J., Oris, R. J., Olson, J., Huang, R., Herczeg, C. K., Giakas, A. M., Green, W. A., Mathew, J. I., Baek, G., et al. (2025) · Spine Open · doi:10.1097/bn9.0000000000000013 · Cited by 2
Applebey, S. V., Xiao, A. G., Reiner, B. C., & Hayes, M. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70177 · Cited by 2
Kang, D., & Choi, D. (2026) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2025.277 · Cited by 1
Wong, H. J., Sim, B., Teo, Y. H., Dalakoti, M., & Sia, C. (2025) · Diabetes Care · doi:10.2337/dci25-0023 · Cited by 1
Self-citationEmerging Treatments for Obesity: the Role of GLP1 Receptor Agonists on Stroke
Mariscal, M., & Testai, F. D. (2025) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-025-01423-9 · Cited by 2
Muscle Mass, Fragility, Weight Loss, and Cancer Treatment
Dougherty, T. P., Klement, R. J., & Champ, C. E. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.4521 · Cited by 1
Frederiksen, K., Berger‐Fleishman, R., Jad, A., Mattar, S. G., & Shetye, B. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100232 · Cited by 2
Demographischer Wandel: Angemessene Arzneimittelversorgung einer alternden Bevölkerung
Thürmann, P., Bencheva, V., & Schmiedl, S. (2025) · Springer eBooks · doi:10.1007/978-3-662-72460-6_3 · Cited by 1
Castaneda, R., Sepulveda, D., Gutiérrez, R. D. J. R., Villamarin, J. L., Bechenati, D., Espinosa, M. A., Verastegui, A., Tama, E., McNally, A. W., Bennett, P. K., et al. (2026) · Diabetology · doi:10.3390/diabetology7010010 · Cited by 1
Soepnel, L. M., Conradie, C. M., Geffen, H., Choo-Kang, C., Bovet, P., Viswanathan, B., Bedu-Addo, K., Boateng, P. O., Dei, O. A., Apusiga, K., et al. (2026) · BMJ Public Health · doi:10.1136/bmjph-2025-003427 · Cited by 1
Weiskirchen, R., & Lonardo, A. (2026) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2026.101458 · Cited by 2
Rai, C., Woodrow, J., O’Neill, C., Lee, I., Ashkani‐Esfahani, S., & Waryasz, G. R. (2026) · The Journal of Foot & Ankle Surgery · doi:10.1053/j.jfas.2026.02.007 · Cited by 2
Chan, Z. H., Omar, A. S., Gill, K., Volucke, G., Azhar, M. M., Haleem, S. M., Sia, J. E., Rahman, O. U., Ahmad, M., Shahid, N., et al. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001209 · Cited by 2
Yaribeygi, H., Maleki, M., Kesharwani, P., Jamialahmadi, T., & Sahebkar, A. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/2770814 · Cited by 1
Baidya, J., Dalton, J., Baek, G., Fano, A. N., Oris, R. J., Huang, R., Herczeg, C. K., Olson, J., Ng, M., Green, W. A., et al. (2026) · European Spine Journal · doi:10.1007/s00586-026-09849-6 · Cited by 2
Metadata
- Authors
- Wong, H. J., Sim, B., Teo, Y. H., Teo, Y. N., Chan, M. Y., Yeo, L. L. L., Eng, P. C., Tan, B. Y. Q., Sattar, N., Dalakoti, M., & Sia, C.-H.
- Affiliations
- National University of Singapore (SG)
- National University Heart Centre Singapore (SG)
- National University Hospital (SG)
- University of Glasgow (GB)
- Corresponding author
- Sia, Ching-Hui
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2025-01-22
- Volume
- 48
- Issue
- 2
- Pages
- 292-300
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4406726472
- Semantic Scholar
- 78bb0c3810a832316cd3e039722f8764a2c24747
- Cited by
- 208
- References
- 38
- Citations by year
- 2026: 136 · 2025: 72
- FWCI
- 28.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis (Writing support)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, obesity, overweight, weight loss, body mass index, waist circumference, diabetes mellitus, treatment effect modifiers, HbA1c, route of administration
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Female, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Body Mass Index, Randomized Controlled Trials as Topic, Overweight, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.